医療従事者の為の最新医療ニュースや様々な情報・ツールを提供する医療総合サイト

GC Pharma Reports Q2 2020 Results

2020年07月30日 PM10:00
このエントリーをはてなブックマークに追加


 

YONGIN, South Korea

GC Pharma (formerly known as Green Cross Corporation) (KRX: 006280), a South Korean biopharmaceutical company, today announced unaudited consolidated financial results for second quarter of 2020.

Second-Quarter Reported Results(1)

Key Figures(1)

Q2 2020

Growth(2)

Total revenues

KRW 360.0 billion

+1.1%

Operating profit

KRW 15.6 billion

-22.0%

K-IFRS profit after taxation

KRW 13.6 billion

T/P

(1) Results from continuing operations (Green Cross MS’ blood bag business has been classified as discontinued operations)

(2) Results and percentages compare to equivalent 2019 period

Financial Highlights

  • Delivered total revenue growth of 1.1% to KRW 360.0 billion (2019 Q2: 356.2 billion), and operation profit decreased 22.0% to KRW 15.6 billion (2019 Q2: 20.0 billion) in the Q2 of 2020
  • Unconsolidated revenues temporary setback impacted by international shipping schedule changes
  • Maintain double-digit growth in consolidated subsidiaries, including Green Cross MS and Green Cross LabCell
  • Green Cross local sales up 3.4% reflecting strong vaccines and CHC segment performance
  • Green Cross international sales temporarily slowed down due to S/H sales of Flu vaccine split Q1 and Q2 unlike prior year, and VZ vaccine expected stronger in the second half
  • Weaker sales of international proteins business continued, as a result of controlling operations
  • Gross profit margin growth driven by increased sales and favourable mix, SG&A rates impact on operating profit margin but expected to progressively ease over the course of the second half

Expected R&D Milestones

  • Hunterase China regulatory decision in Q3
  • GreenGeneF China regulatory decision in Q4
  • Hunterase ICV Japan regulatory decision in Q4
  • IVIG 10% US BLA submission in Q4

About GC Pharma

GC Pharma is a biopharmaceutical company that delivers life-saving and life-sustaining protein therapeutics and vaccines. Headquartered in South Korea, GC Pharma is the largest plasma protein product manufacturer in Asia and has been dedicated to quality healthcare solutions more than half a century. Green Cross Corporation updates its corporate brand as GC Pharma in early 2018. Green Cross Corporation remains the company’s registered, legal name.

This release includes forward-looking statements, which express the current beliefs and expectations of GC Pharma’s management. Such statements speak only as of the date on which they are made and the company undertakes no obligation to update or revise any forward-looking statement, whether as a result of new information, future events or otherwise.

View source version on businesswire.com: https://www.businesswire.com/news/home/20200730005378/en/

CONTACT

Investor/Media Contact

HyunGoo Kang

+82 31 260 9382

gookang@greencross.com

WooSub Shin

+82 31 260 9397

isswoo@greencross.com

Yelin Jun

+82 31 270 1505

yelin@greencross.com

JiWoong Kim

+82 31 260 0759

yoholiday@greencross.com

Hansaem Kim

+82 31 260 9392

hs.kim@gccorp.com

Related Posts Plugin for WordPress, Blogger...

同じカテゴリーの記事 

  • 武田通过与Moderna和日本政府合作,在日本扩大COVID-19疫苗供货
  • ABEC将向百因诺生物交付业内首台6000L一次性生物反应器
  • Ocular Therapeutix™ and AffaMed Therapeutics Announce License Agreement and Collaboration for DEXTENZA® and OTX-TIC in Asia
  • The McQuade Center for Strategic Research and Development Enters Collaboration Agreement with Rugen Holdings (Cayman) Limited to Develop Novel Treatment for Patients with Diverse Psychiatric Disorders
  • 国連世界都市デーを機に、G20のアーバン20(U20)エンゲージメント・グループがCOVID-19を受けて「世界都市強靭性基金」の創設を発表